TherapeuticsMD Q1 net loss narrows to $2.3M from $17.9M; continuing ops loss $0.24/share

TherapeuticsMD, Inc.

2023-Q1 EPS reported -$0.37 vs consensus $0.06 ▼ miss (-704.6%)

Net loss from continuing operations $2.3M ($0.24/share) vs $17.9M ($2.08) in Q1 2022.
License and service revenues $0.4M, down from $0.7M due to transition to royalty-based business.
Total operating expenses fell 82.8% to $3.1M, reflecting business transformation and reduced infrastructure.
Net loss from discontinued ops $1.3M ($0.13/share) vs $31.1M ($3.62), as wind-down continues.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

TherapeuticsMD, Inc. reported first quarter ended March 31, 2023 results: revenue $0.4 million, net income $2.3 million, EPS $0.24 per basic and diluted common share.

Period: first quarter ended March 31, 2023
Revenue: $0.4 million
Net income: $2.3 million
EPS: $0.24 per basic and diluted common share
Result: reported results

Exact text from the filing

Net loss from continuing operations was $2.3 million for the quarter ended March 31, 2023, or $0.24 per basic and diluted common share, compared to a net loss from continuing operations of $17.9 million, or $2.08 per basic and diluted common share, for the comparable period in 2022. License and Service Revenues from Continuing Operations • License and service revenues from continuing operations, which are revenues related to license agreements, were $0.4 million for the quarter ended March 31, 2023, compared to $0.7 million in license and service revenue related to sales to other licensees for the first quarter of 2022.

View on SEC.gov

16 earnings releases filed in the last 30 days. Browse all earnings releases →

TherapeuticsMD, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-145019

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.